Cartesian Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cartesian Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $4.69M.
- Cartesian Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $14.58M.
- Cartesian Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $124.66M.
- Cartesian Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-06-30 was $21.48M.
- Cartesian Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $124.44M.
- Cartesian Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2019 was $30.94M.
- Cartesian Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2016 was $64.47M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $4.69M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $14.58M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $124.44M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $124.66M 10-Q · filed 2025-11-06 | |
| 2022-06-30 | $21.48M 10-Q · filed 2022-11-03 | |
| 2019-12-31 | $30.94M 10-K · filed 2022-03-10 | |
| 2019-03-31 | $30.94M 10-Q · filed 2020-11-05 | |
| 2016-12-31 | -$36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $64.47M 10-K · filed 2019-03-15 |
| 2016-09-30 | $3.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |